Risk of heart failure associated with dopamine agonists: A nested case-control study

Drugs and Aging

Volumn 30, Issue 9, 2013, Pages 739-745

  Hsieh, P H ^a   Hsiao, F Y ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

AGED; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

AGED; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DOPAMINE AGONISTS; FEMALE; HEART FAILURE; HUMANS; MALE; ODDS RATIO; RISK; TIME FACTORS;

EID: 84883238092     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0102-z     Document Type: Review

References (13)

1. Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;68(6):685-9.
2. US Food and Drug Administration. FDA drug safety communication: ongoing safety review of Parkinson's drug Mirapex (pramipexole) and possible risk of heart failure. http://www.fda.gov/Drugs/DrugSafety/ucm319779.htm#data. Accessed 16 Jan 2013.
3. Renoux C, Dell'Aniello S, Brophy JM, Suissa S. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf. 2012;21(1):34-41.
4. Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. Pharmacol Res. 2012;65(3):358-64.
5. Hsiao FY, Yang CL, Huang YT, Huang WF. Using Taiwan's national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal. 2007;15(2):99-108.
6. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29-38.
7. Trifiro G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf. 2012;35(2):159-71.
8. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med. 2005;353(18):1976-7.
9. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology. 2003;61(6):859-61.
10. Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol. 2000;57(5):729-32.
11. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-53.
12. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236-42.
13. Hsiao FY, Tsai YW, Wen YW, Chen PF, Chou HY, Chen CH, et al. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf. 2010;19(8):786-91.